Fig. 5: In vivo TIGIT blockade enhances the antitumor efficacy of BCMA-CAR-T therapy in MM mouse models. | Cell Death & Disease

Fig. 5: In vivo TIGIT blockade enhances the antitumor efficacy of BCMA-CAR-T therapy in MM mouse models.

From: Preclinical evaluation of TIGIT as a target to enhance efficacy and mitigate T cell exhaustion in multiple myeloma following BCMA-CAR-T therapy

Fig. 5

A Schematic diagram of the animal model and experimental workflow. B Bioluminescence images of tumor burden at different time points after CAR-T infusion (day 0 indicates the infusion day). C Changes in mouse body weight over time. D Kaplan–Meier survival analysis of mice up to 60 days after CAR-T infusion.

Back to article page